Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemoglobin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

NCT00009581
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Acetylcholine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

The Diabetes Medication Adherence Promotion Intervention Trial

NCT02458495
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes MAP Intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

NCT00005783
View directory record Official record
Conditions
Hemoglobin SC Disease, Sickle Cell Anemia
Interventions
Recombinant-methionyl human stem cell factor
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 7:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Noninvasive Hemoglobin Monitor in the ER

NCT02421250
View directory record Official record
Conditions
Hemoglobin
Interventions
Radical-7 Noninvasive Hgb Monitor
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

NCT01141192
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
vitamin D3, cholecalciferol, Inactive comparator
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

NCT00433628
View directory record Official record
Conditions
HIV, Diabetes, Hyperglycemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients

NCT01079247
View directory record Official record
Conditions
Burn Injury
Interventions
Restrictive transfusion threshold, Liberal transfusion threshold
Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Colton, California • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

NCT01656759
View directory record Official record
Conditions
Osteoarthritis, Intraoperative Bleeding
Interventions
Evicel Fibrin Spray
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

NCT02888171
View directory record Official record
Conditions
Chronic Kidney Disease, Iron Deficiency, Anemia
Interventions
ferric citrate, ferrous sulfate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

Restrictive Versus Liberal Transfusion Protocol in Infants Undergoing Cardiac Surgery

NCT01484886
View directory record Official record
Conditions
Impaired Oxygen Delivery, Congenital Heart Disease
Interventions
Red blood cell transfusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Up to 7 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 9, 2026, 7:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision Aid for Therapeutic Options In Sickle Cell Disease

NCT02326597
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Hemoglobin SS, Hemoglobin SC, Hemoglobin Beta Thalassemia
Interventions
Decision Aid Tool, Standard Practice
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placental Transfusion in Term Infants: A Pilot Study

NCT01924572
View directory record Official record
Conditions
Anemia
Interventions
cord clamping at 2 minutes, cord clamping at 5 minutes, cord milking
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Sep 9, 2026, 7:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Timing of Cord Clamping and Neonatal Hemoglobin

NCT00371228
View directory record Official record
Conditions
Anemia
Interventions
Delay of umbilical cord clamping
Procedure
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 34 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Placebo, Sitagliptin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease
Interventions
Fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Milking the Umbilical Cord at Term Cesarean Birth

NCT01630993
View directory record Official record
Conditions
Anemia
Interventions
Umbilical Cord Milking
Other
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

NCT02561312
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Interventions
Rapid manual partial exchange transfusion, Simple Transfusion
Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

NCT03263091
View directory record Official record
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
30
States / cities
Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated No phase listed Observational

StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole Blood

NCT05118048
View directory record Official record
Conditions
Sepsis, Anemia, Bleeding, Erythrocytosis
Interventions
Lactate, Hemoglobin, Hematocrit
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Timeline
2021
U.S. locations
3
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Not yet recruiting Phase 4 Interventional

REDUCER Trial (TXA in Urethroplasty)

NCT07501884
View directory record Official record
Conditions
Urethral Stricture, Urethral Diseases
Interventions
Tranexamic Acid, Urethroplasty
Drug · Procedure
Lead sponsor
Amjad Alwaal, MD, MSc, FRCSC, FACS
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 9, 2026, 7:24 AM EDT